The Impact of SARS-CoV-2 Immune Status and Societal Restrictions in Controlling COVID-19 across the World.
COVID pass
SARS-CoV-2 antibodies
SARS-CoV-2 antigen test
societal restrictions
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
23 Aug 2023
23 Aug 2023
Historique:
received:
01
07
2023
revised:
04
08
2023
accepted:
16
08
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
To control the COVID-19 pandemic, many countries implemented vaccination and imposed societal restrictions both at the national level and for international travel. As a check of corona status, COVID passes have been issued. A COVID pass could be obtained when either fully vaccinated against COVID-19, or after recovering from a documented COVID-19 episode, or after a recent (24-48 h) negative SARS-CoV-2 antigen test. A global analysis of SARS-CoV-2 immune status determined by past infection and/or vaccination, vaccination rates, as well as societal restrictions in controlling the COVID-19 pandemic is presented. The data show that across the world, vaccination was more effective in reducing SARS-CoV-2 infections with the delta variant than the omicron variant. Strict societal restrictions could control spread of the virus, but relief of the restrictions was associated with an increase in omicron infections. No significant difference in SARS-CoV-2 infections were found when comparing countries or territories which did or did not implement a COVID pass.
Identifiants
pubmed: 37766084
pii: vaccines11091407
doi: 10.3390/vaccines11091407
pmc: PMC10535952
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Emerg Infect Dis. 2022 Oct;28(10):1990-1998
pubmed: 36048774
JCI Insight. 2021 May 10;6(9):
pubmed: 33822773
J Travel Med. 2022 May 31;29(3):
pubmed: 35262737
Lancet Respir Med. 2021 Dec;9(12):e121
pubmed: 34774187
JAMA. 2023 Jun 6;329(21):1817
pubmed: 37195734
Saudi Pharm J. 2021 May;29(5):391-409
pubmed: 33897262
JAMA. 2020 Jun 9;323(22):2243-2244
pubmed: 32374358
Cytokine Growth Factor Rev. 2020 Jun;53:1-9
pubmed: 32487439
JMIR Public Health Surveill. 2023 Feb 10;9:e38371
pubmed: 36395334
World J Clin Cases. 2022 Jan 7;10(1):1-11
pubmed: 35071500
Health Econ Policy Law. 2022 Jan;17(1):95-106
pubmed: 34311803
Glob Health Res Policy. 2020 Jul 1;5:33
pubmed: 32617414
Int J Surg. 2020 Apr;76:128-129
pubmed: 32169574
Health Policy. 2022 Aug;126(8):755-762
pubmed: 35680529
J Korean Med Sci. 2023 Mar 20;38(11):e87
pubmed: 36942395
BMC Public Health. 2022 Mar 22;22(1):565
pubmed: 35317756
Vaccines (Basel). 2021 Aug 03;9(8):
pubmed: 34451973
BMJ. 2022 Jan 11;376:o66
pubmed: 35017144
Front Public Health. 2021 Jan 20;8:582140
pubmed: 33553086
Front Public Health. 2023 Mar 20;11:1085451
pubmed: 37020822
J Travel Med. 2021 Oct 11;28(7):
pubmed: 34343308
Nat Commun. 2022 Aug 12;13(1):4738
pubmed: 35961956
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Nature. 2022 Feb;602(7895):22-25
pubmed: 35110764
Nature. 2023 Jan;613(7942):130-137
pubmed: 36517599
Gene Rep. 2020 Jun;19:100682
pubmed: 32300673
Pol Arch Intern Med. 2023 May 23;133(5):
pubmed: 36602857
Nat Hum Behav. 2021 Apr;5(4):529-538
pubmed: 33686204
PLoS One. 2021 Jan 7;16(1):e0243701
pubmed: 33411737
Glob Public Health. 2020 Sep;15(9):1413-1416
pubmed: 32564670
Viruses. 2022 Apr 15;14(4):
pubmed: 35458551
J Med Virol. 2023 Jan;95(1):e28118
pubmed: 36056540
Int J Surg. 2020 Apr;76:71-76
pubmed: 32112977
Hum Vaccin Immunother. 2021 Nov 2;17(11):4108-4111
pubmed: 34292128
EMBO Mol Med. 2020 Jun 8;12(6):e12634
pubmed: 32375201
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
Nat Med. 2022 Feb;28(2):232-235
pubmed: 35022575
BMJ. 2022 Aug 2;378:e070695
pubmed: 35918098
BMJ. 2022 Aug 2;378:o1806
pubmed: 35918084
PLoS One. 2022 Feb 17;17(2):e0263820
pubmed: 35176031
J Med Virol. 2020 Nov;92(11):2465-2472
pubmed: 32525568
Int J Infect Dis. 2023 Jan;126:31-38
pubmed: 36372363